KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

GoodRx Holdings (GDRX) Revenue (2019 - 2026)

GoodRx Holdings' Revenue history spans 7 years, with the latest figure at $194.8 million for Q4 2025.

  • On a quarterly basis, Revenue fell 1.91% to $194.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $796.9 million, a 0.57% increase, with the full-year FY2025 number at $796.9 million, up 0.57% from a year prior.
  • Revenue hit $194.8 million in Q4 2025 for GoodRx Holdings, down from $196.0 million in the prior quarter.
  • Over the last five years, Revenue for GDRX hit a ceiling of $213.3 million in Q4 2021 and a floor of $160.4 million in Q1 2021.
  • Historically, Revenue has averaged $192.6 million across 5 years, with a median of $195.2 million in 2021.
  • Biggest five-year swings in Revenue: surged 43.26% in 2021 and later fell 13.67% in 2022.
  • Tracing GDRX's Revenue over 5 years: stood at $213.3 million in 2021, then decreased by 13.67% to $184.1 million in 2022, then rose by 6.81% to $196.6 million in 2023, then increased by 0.99% to $198.6 million in 2024, then fell by 1.91% to $194.8 million in 2025.
  • Business Quant data shows Revenue for GDRX at $194.8 million in Q4 2025, $196.0 million in Q3 2025, and $203.1 million in Q2 2025.